
Brickell Biotech BBI
Annual report 2023
added 03-15-2024
Brickell Biotech Depreciation & Amortization 2011-2026 | BBI
Annual Depreciation & Amortization Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41 K | 30 K | 22 K | 10 K | 28 K | 151 K | 793 K | 1.12 M | 1.16 M | 1.66 M | 2.21 M | 1.98 M | 2.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.3 M | 10 K | 885 K |
Quarterly Depreciation & Amortization Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 10 K | - | - | 13 K | 7 K | - | - | 8 K | 1 K | - | 9 K | 6 K | 3 K | - | 25 K | 21 K | 13 K | - | 37 K | 119 K | 64 K | - | 722 K | 526 K | 267 K | - | 836 K | 556 K | 277 K | - | 884 K | 595 K | 301 K | - | 1.33 M | 940 K | 467 K | - | 1.73 M | 1.2 M | 620 K | - | 1.69 M | 981 K | 493 K | - | 1.75 M | 1.16 M | 579 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.75 M | 1 K | 521 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
112 K | $ 3.44 | 2.99 % | $ 303 M | ||
|
Amgen
AMGN
|
5.17 B | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 19.23 | -1.38 % | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Amarin Corporation plc
AMRN
|
3.02 M | $ 14.6 | 0.76 % | $ 6.06 B | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.4 | 2.19 % | $ 357 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Benitec Biopharma
BNTC
|
66 K | $ 11.19 | 1.91 % | $ 461 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
363 K | $ 4.42 | 4.25 % | $ 734 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 2.82 | -4.08 % | $ 3.29 M | ||
|
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M |